vTv Therapeutics says FDA grants orphan drug designation to HPPD in sickle cell disease
Bitget2026/10/07 20:01FDA granted Orphan Drug Designation to vTv Therapeutics’ HPPD for sickle cell disease. HPPD is an oral Nrf2/Bach1 modulator in preclinical development. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. vTv Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610071601PRIMZONEFULLFEED9841475) on October 07, 2026, and is solely responsible for the information contained therein.
- FDA granted Orphan Drug Designation to vTv Therapeutics’ HPPD for sickle cell disease.
- HPPD is an oral Nrf2/Bach1 modulator in preclinical development.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cold wave and rising fuel costs drive electricity prices in northeastern Japan and Tokyo to a four-year high
Japan's spot electricity prices surged to multi-year highs over the weekend.
Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail
Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.
Canaccord Genuity: Lowers Oklo's target price to $66
Crypto prices
More
